secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001387131-23-009623
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharma Q2 2023 net loss $28.4M; completes acquisition of two migraine products
--------------------------------------------------------------------------------

- Net loss $28.4M ($2.68/sh) vs $27.4M ($7.64/sh) in Q2 2022; R&D expense rose to $22.0M from $16.6M.
- Cash & equivalents $25.6M at June 30, down from $120.2M at Dec 31, 2022; raised $7.0M in Aug 2023 offering.
- Closed acquisition of Zembrace SymTouch and Tosymra from Upsher-Smith for $15M plus $10M inventory; trailing sales ~$30M.
- Enrolled four CNS trials: RESILIENT fibromyalgia (Q4 topline), PREVAIL Long COVID (Q3), PREVENTION chronic migraine (Q4), UPLIFT MDD (Q4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123009623/0001387131-23-009623-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123009623/tnxp_8k-081023.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-009623

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer